Para-probiotics as Novel Anti-Inflammatory Agents: Insight into Health Benefits and Therapeutic Applications

  • 0Department of Pharmaceutical Technology, Bharat Technology, Uluberia, 711316, West Bengal, India.

|

|

Summary

This summary is machine-generated.

Para-probiotics, or non-viable microbial cells, offer a safe and stable alternative to traditional probiotics for managing inflammation. These agents modulate immune responses and enhance gut health, showing promise for various health applications.

Area Of Science

  • Immunology and Microbiology
  • Gastroenterology
  • Nutraceutical Science

Background

  • Para-probiotics, defined as non-viable microbial cells or their components, are gaining attention for their health benefits.
  • Unlike live probiotics, para-probiotics present enhanced safety, stability, and applicability, particularly for vulnerable populations.
  • They modulate immune responses and strengthen the intestinal barrier via interactions with host receptors.

Purpose Of The Study

  • To review the current evidence on the anti-inflammatory properties of para-probiotics.
  • To highlight preclinical and clinical studies investigating their efficacy.
  • To discuss technological aspects of para-probiotic production.

Main Methods

  • Literature review synthesizing existing research on para-probiotics.
  • Analysis of studies focusing on immune modulation and anti-inflammatory mechanisms.
  • Examination of production technologies and applications in functional foods.

Main Results

  • Para-probiotics demonstrate significant anti-inflammatory and immunomodulatory effects by influencing key signaling pathways (e.g., NF-κB, MAPKs).
  • They enhance mucosal defense and intestinal barrier integrity.
  • Studies indicate reduced risks and improved stability compared to live probiotics.

Conclusions

  • Para-probiotics are a safe, stable, and effective alternative to traditional probiotics for managing inflammation-associated diseases.
  • Further research is needed to fully elucidate their mechanisms of action.
  • Their properties support incorporation into functional foods and nutraceuticals.

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management 01:29

521

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents 01:20

1.1K

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Microorganisms in Medicine and Therapeutics 01:29

982

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy 01:30

643

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents 01:18

425

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents 01:29

493

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...